Sygnature Discovery Ltd. and Ube Corp. have established a collaboration on a hit-to-lead program to identify SHP2 degraders. The aim is to develop potent bifunctional compounds with excellent ADME and pharmacokinetic properties for efficient degradation of SHP2, a tyrosine-specific phosphatase implicated in human cancers.
Novo Nordisk A/S and Valo Health Inc. have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases. The collaboration will leverage Valo’s Opal Computational Platform, including access to real-world patient data, artificial intelligence (AI)-enabled small-molecule discovery and Biowire human tissue modeling platform designed to speed up the discovery and development process.
Phylex Biosciences Inc. has announced plans to pursue the development of a nanoparticle mRNA vaccine against the Nipah virus. Last year, the company published proof of principle for its second-generation nanoparticle mRNA vaccine against the SARS-CoV-2 delta virus.
The autosomal dominant form of osteopetrosis, referred to as autosomal dominant osteopetrosis type 2 (ADO2), is caused by single allele dominant negative mutations of the CLCN7 gene. In a recent paper, researchers from Sisaf Ltd. detailed the development and preclinical evaluation of novel silicon stabilized hybrid lipid nanoparticles (sshLNPs), SIS-101-ADO, designed to deliver small interfering RNA (siRNA) specific against the human CLCN7 G215R mRNA.
Mitochondria regulate many processes that are altered in cancer cells, from metabolism to oxidative stress to apoptosis. The metabolic reprogramming in cancer cells promotes an immunosuppressive environment that drives cancer progression. However, in a recent study, researchers from the Salk Institute of Biological Sciences have identified succinate as a metabolite that accumulated due to specific disturbances in the mitochondrial electron transport chain.
Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has divulged naphthyridine derivatives acting as ATR kinase inhibitors reported to be useful for the treatment of cancer, psoriasis, keloids and benign prostatic hyperplasia.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.